Number of GranuFlo/NaturaLyte Lawsuits Continues to Grow, Baron and Budd Reports

More Than 5,000 Cases Now Being Handled in Massachusetts

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

(PRWEB) August 22, 2014

According to a July 15 article in the Boston Herald, the number of lawsuits involving the use of dialysis products GranuFlo and NaturaLyte being heard in two Massachusetts courts now exceeds 5,000, the national law firm of Baron and Budd reports. The plaintiffs allege that the manufacturer of these products, Fresenius Medical Care – which also owns thousands of dialysis clinics across the United States – knew about health risks associated with GranuFlo and NaturaLyte, yet chose not to warn dialysis clinics. (http://bostonherald.com/business/healthcare/2014/07/suits_target_waltham_maker_of_dialysis_solutions)

Plaintiffs have brought a combined 5,494 cases against Fresenius Medical Care, the manufacturer of the drugs. Of these cases, 3,694 of them have been filed in Middlesex Superior Court, with another 1,800 cases filed in the U.S. District Court in Boston. (In re: Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

The plaintiffs in the cases cite a memo that was circulated internally within Fresenius concluding that use of GranuFlo could result in serious cardiac issues in patients. Use of the products can lead to a condition known as metabolic alkalosis, a dangerous increase in the blood’s bicarbonate levels. The condition can increase the risk of sudden cardiac arrest, heart attacks and additional cardiovascular problems.

The U.S. Food and Drug Administration (FDA) investigated these medical devices in 2012, which resulted in a Class 1 recall regarding the labeling of the products. According to the article, a Fresenius spokesperson said that the FDA has neither requested that products be taken off the market nor suggested any sort of change to the formulation of the products.

“What the Fresenius spokesman said in the article does not take away from the fact that many, many people have suffered devastating health issues after undergoing dialysis treatments that included GranuFlo or NaturaLyte,” said Laura Baughman, shareholder at the national law firm of Baron and Budd. “The growing number of cases highlights just how serious this problem really is.”

The national law firm of Baron and Budd wants you to know that you may have legal avenues to pursue if you or someone close to you has suffered health issues after undergoing dialysis treatments that included GranuFlo and NaturaLyte. Please call 1-866-472-9108 or visit our website at http://baronandbudd.com/areas-of-practice/pharmaceuticals/granuflo-lawyer/ for more information.

ABOUT BARON & BUDD, P.C.

The attorneys at Baron and Budd have been Protecting What’s Right for consumers for more than 35 years. Over the years, our national law firm has built a successful track record representing people who have been harmed by corporate wrongdoing. The firm’s pharmaceutical lawyers recently represented over 7,000 patients harmed by using the drug Avandia. Previously, Baron & Budd played a prominent role in litigation related to the diet drug Fen-Phen. As a result, the case settled for an amount valued at more than $1.275 billion (In Re Diet Drugs (Phentermine | Fenfluramine | Dexfenfluramine) Products Liability Litigation, MDL No. 1203 (E.D. Pa.).


Contact